Status:

COMPLETED

Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer

Lead Sponsor:

City of Hope Medical Center

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Kidney Cancer

Eligibility:

All Genders

Brief Summary

This research trial studies the development of a blood test for detecting anti-insulin-like growth factor II mRNA binding protein 3 (anti-IMP3) antibody and micro ribonucleic acid (microRNA) in patien...

Detailed Description

PRIMARY OBJECTIVE: I. To develop a blood test by monitoring the titer of IMP3 autoantibody and/or microRNA (miRNA)/small non-coding RNA (snRNA) expression in patients' serum for the early detection o...

Eligibility Criteria

Inclusion

  • Metastatic RCC Patients' Serum Cohort:
  • a. Serum samples from patients with metastatic RCC prior to surgical removal of the metastatic and/or primary lesions
  • b. Serum samples from patients with localized RCC prior to surgical removal of the lesions
  • c. Discarded donors' and patients' discarded/leftover plasma/serum samples from blood bank and other Department of Pathology laboratories
  • d. Serum samples from patients with metastatic RCC who had nephrectomies or/and RCC-related biopsies in the referring hospitals
  • Metastatic RCC Patients' Tissue Cohort:
  • Formalin-fixed paraffin-embedded (FFPE) and/or frozen primary and/or metastatic RCC tissue samples from the corresponding patients serum who are included in inclusion criteria (a-b)
  • FFPE and/or frozen benign renal tissue samples which are nearby the tumor and remove during surgical procedures from the corresponding patients who are included in inclusion criteria (a-b)
  • Discarded/leftover FFPE and frozen renal tissue samples from Department of Anatomic Pathology and its Tumor Bank
  • FFPE primary and/or metastatic RCC tissue samples (unstained slides) from the corresponding patients who are included in inclusion criteria (d)

Exclusion

  • Not applicable

Key Trial Info

Start Date :

July 1 2008

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

November 15 2017

Estimated Enrollment :

155 Patients enrolled

Trial Details

Trial ID

NCT00806650

Start Date

July 1 2008

End Date

November 15 2017

Last Update

December 8 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

City of Hope Medical Center

Duarte, California, United States, 91010-3000

Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer | DecenTrialz